KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Intangibles (2016 - 2025)

Travere Therapeutics' Intangibles history spans 13 years, with the latest figure at $113.9 million for Q4 2025.

  • For Q4 2025, Intangibles rose 9.52% year-over-year to $113.9 million; the TTM value through Dec 2025 reached $113.9 million, up 9.52%, while the annual FY2025 figure was $113.9 million, 9.52% up from the prior year.
  • Intangibles reached $113.9 million in Q4 2025 per TVTX's latest filing, up from $109.4 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $162.9 million in Q1 2023 to a low of $97.1 million in Q4 2022.
  • Average Intangibles over 5 years is $126.2 million, with a median of $111.7 million recorded in 2025.
  • Peak YoY movement for Intangibles: tumbled 37.88% in 2024, then increased 9.52% in 2025.
  • A 5-year view of Intangibles shows it stood at $148.4 million in 2021, then tumbled by 34.6% to $97.1 million in 2022, then grew by 7.59% to $104.4 million in 2023, then dropped by 0.45% to $104.0 million in 2024, then rose by 9.52% to $113.9 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Intangibles are $113.9 million (Q4 2025), $109.4 million (Q3 2025), and $105.6 million (Q2 2025).